Friday, 28 February 2020

Glenmark receives tentative ANDA approval for Clindamycin Phosphate Foam, 1%

20 June 2019 | News

It is a generic version of EVOCLIN® Foam, 1%, of Mylan Pharmaceuticals Inc.

Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration for Clindamycin Phosphate Foam, 1%, a generic version of EVOCLIN® Foam, 1%, of Mylan Pharmaceuticals Inc.

According to IQVIATM sales data for the 12 month period ending April 2019, the EVOCLIN® Foam, 1% market achieved annual sales of approximately $17.0 million.

Glenmark’s current portfolio consists of 156 products authorized for distribution in the U.S. marketplace and 59 ANDA’s pending approval with the USFDA.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account